The earlier colorectal cancer and its precancerous lesions are detected, the better. For this purpose, new immunological tests for hidden traces of blood in the stool have been in use since this year. These tests only deliver positive results if specific threshold values of hemoglobin are exceeded. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have compared nine of these tests. Their result: All nine tests detect the vast majority of colorectal cancer cases and also many of its precancerous lesions. However, the manufacturers’ specifications of the hemoglobin value above which there is a suspected case of colorectal cancer vary widely. Adjusting the thresholds, the scientists showed that all tests deliver very similar results. Even a smartphone test that functions without laboratory analysis can compete with test results from the laboratory.
Presently, there are numerous different immunological tests on the market. “Until now, it has been unclear whether and how much the available tests differ from each other,” said Brenner. Therefore, the epidemiologist and his team made a direct comparison of nine tests.
Brenner’s result is that all nine tests detect the vast majority of colorectal cancer cases and also many precancerous lesions. If one sticks to the threshold values specified by the manufacturers for a test to be considered positive, then the rates of positive results vary widely.
However, when the scientists adjusted the threshold values in their evaluation, the tests all delivered very similar results. “In this work, we present, for the first time, a worldwide unique direct comparison of the diagnostic performance of a large number of quantitative tests in the same large group of study participants,” Brenner said. He continued that these figures could be used to derive countrywide recommendations for threshold values for individual tests.
“In this work, Brenner and colleagues are giving precise recommendations for further improvements in colorectal cancer screening,” emphasized Michael Baumann, DKFZ’s Chairman and Scientific Director. “Since colonoscopy, which continues to be the gold standard in screening for colorectal cancer, is rather laborious, it is important to also offer people a screening examination with a lower threshold.”
Five of the nine tests require analysis in a laboratory. The remaining four can be conducted and evaluated directly at the family doctor’s or urologist’s office. Even the test that uses a smartphone app for evaluation delivered reliable results, at least if it was carried out by qualified staff.
Colorectal cancer is the third most frequent type of cancer worldwide. Each year, approximately 1.4 million people are newly diagnosed with it; 700,000 succumb to the disease. It also holds true for colorectal cancer that the earlier it is detected, the better the chances are of curing it. Therefore, people insured with statutory health insurance in Germany are entitled to an endoscopic examination of the colon (colonoscopy) starting at 55 years of age. Colonoscopy is considered to be the most accurate method for detecting colorectal cancer and its precursors. However, the testing method is laborious and many patients are reluctant to have it done. Only 20 to 30 percent of those eligible actually take advantage of the screening examination.
New immunological testing methods that have been covered by statutory health insurance since April of this year are intended to help encourage more people to undergo a screening exam.
“In our neighboring country of the Netherlands, this already works very well,” Brenner reports. People are sent an individual invitation to participate in the program and the test is directly sent with the letter. This approach achieves participation rates of more than 60 percent. Germany is presently a far cry from that.
Anton Gies, Katarina Cuk, Petra Schrotz-King, Hermann Brenner: Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening. Gastroenteroloy 2017. DOI: 10.1053/j.gastro.2017.09.018
An image for this press release is available at:
Caption: Colon cancer under the microscope
Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Lutz Langbein, DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: email@example.com). Any commercial use is prohibited.
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.